Ticagrelor pharmaceutical composition and preparing method thereof

A technology of ticagrelor and a composition, applied in the field of pharmaceutical preparations, can solve the problems of inability to achieve rapid onset of action, inability to maintain continuous efficacy and the like

Active Publication Date: 2016-10-12
SICHUAN HAISCO PHARMA CO LTD
View PDF6 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After analyzing the above-mentioned patented technologies, among them, patent CN102657629B and patent CN103860504A, although they can prolong the in vivo action time, they cannot achieve rapid onset of action
Although the patent CN103520164B can achieve rapid onset of effect, once a day administration cannot maintain continuous effectiveness for 24 hours

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ticagrelor pharmaceutical composition and preparing method thereof
  • Ticagrelor pharmaceutical composition and preparing method thereof
  • Ticagrelor pharmaceutical composition and preparing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Ticagrelor pharmaceutical composition (specification 160mg):

[0073]

[0074]

Embodiment 2

[0076] Ticagrelor pharmaceutical composition (specification 175mg):

[0077]

Embodiment 3

[0079] Ticagrelor pharmaceutical composition (specification 180mg):

[0080]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a sustained-release preparation composition of an anticoagulant drug ticagrelor (also called brilinta) and a preparing method thereof. The composition comprises ticagrelor and other pharmaceutical accessories. The composition is characterized in that the composition can be quick in acting, also can ensure persistent effectivity within 24 hours, and further can reduce Cmax based on guarantee of the effective plasma concentration, thereby improving patient compliance and reducing drug safety problem in the premise without reduction of curative effect.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a ticagrelor (also known as ticagrelor) oral sustained-release preparation pharmaceutical composition and a preparation method thereof. Background technique [0002] Ticagrelor, also known as ticagrelor, the chemical name is (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorobenzene Base) cyclopropyl] amino}-5-propylthio-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy) -1,2-cyclopentanediol, the chemical structure is as shown in formula I: [0003] [0004] Ticagrelor belongs to the class of cyclopentyltriazolopyrimidines and is the first reversible P 2 Y 12 Platelet inhibitors, mainly used to reduce thrombotic cardiovascular events (cardiovascular death, myocardial infarction) in patients with acute coronary syndrome (ACS) (including unstable angina, non-ST segment myocardial infarction, ST segment elevation myocardial infarction) and s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K9/24A61K9/26A61K9/52A61K47/38A61K47/26A61K47/32A61K47/02A61K47/36A61K47/34A61P9/10
CPCA61K9/0002A61K9/1611A61K9/1623A61K9/1652A61K9/167A61K9/2077A61K9/2086A61K9/485A61K9/4858A61K9/4866A61K31/519A61K47/02A61K47/26A61K47/32A61K47/36A61K47/38
Inventor 向志祥黄智龙何夏凯罗杰刘小枫
Owner SICHUAN HAISCO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products